Vesugen
Also known as: Peptídeo vascular
Molecular Identifiers
Overview
Vascular bioregulatory tripeptide developed by the Khavinson group. Regulates gene expression in vascular endothelium and supports the integrity of blood vessel walls. Used in short cycles for vascular system protection and support.
Vesugen is proposed as a peptide bioregulator of vascular endothelium, acting on gene expression in vascular tissue and supporting the integrity and elasticity of vessel walls. Reported effects include normalization of endothelial function, modulation of nitric oxide production, and support for microcirculation, in short cyclic protocols. It is often combined with Cardiogen in cardiovascular bioregulation strategies.
Outside Russia, Vesugen has no regulatory approval or recognized clinical indication. It is dispensed by compounding pharmacies as off-label use in 10 to 20 day cycles, repeated 2 to 4 times per year, generally subcutaneously or intramuscularly. Available scientific evidence is concentrated in publications from the Russian Khavinson peptide school, with few independent human clinical trials.
Within the Khavinson family, Vesugen is most often compared to Cardiogen on the cardiovascular axis: Vesugen (the Lys-Glu-Asp tripeptide) is presented with a focus on the vascular endothelium and vessel wall, while Cardiogen (the Ala-Glu-Asp-Arg tetrapeptide) is described as acting on the cardiomyocyte and the myocardium. All of this comparative literature is largely Russian and preclinical.
KED Lys-Glu-Asp Half-life
~2-4 hours
Administration Route
Subcutaneous or intramuscular
Category
Specialized Research
Mechanism of Action
- Regulation of gene expression in vascular endothelium
- Support for vascular wall integrity and elasticity
- Normalization of endothelial function and nitric oxide production
- Modulation of vascular tone and microcirculation
- Bioregulatory effect on the circulatory system
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 1-2 capsules orally (0.2 g per capsule, containing AKS-2 peptide complex) |
| Frequency | 1-2 times daily, with meals |
| Timing | With meals |
| Duration | 10-30 days per cycle, repeat the course every 4-6 months |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Injection site pain
- Local redness (rare)
Product Properties
| Purity | >95% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles. |
Presentations & Preparation
Vials of Vesugen found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on Vesugen.
Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro
Lin'kova NS, Drobintseva AO, Orlova OA, Kuznetsova EP, Polyakova VO, Kvetnoy IM, Khavinson VKh
Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging
Khavinson VKh, Tarnovskaia SI, Lin'kova NS, Guton EO, Elashkina EV
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
B7-33
Bronchogen
1-2 capsules orally (0.2 g per capsule, containing AKS-B peptide complex) · 1-2 times daily, with meals
Cardiogen
Chonluten
1-2 capsules orally (0.2 g per capsule, containing bronchial tissue peptide complex) · 1-2 times daily, with meals
Crystagen
1-2 capsules orally (0.2 g per capsule, containing AKS-6 peptide complex) · 1-2 times daily, before meals